Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer

Y. Shimizu, T. Nakanishi, K. Sasamoto, S. Kondo

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To investigate the effectiveness of single-agent intravenous bevacizumab (7.5 mg/kg every three to four weeks) for palliating symptomatic malignant ascites caused by recurrent ovarian cancer, the authors examined the cases retrospectively. Materials and Methods: Five patients with recurrent ovarian cancer and malignant ascites were treated with bevacizumab. Results: A total of 23 bevacizumab infusions were administered for the patients, and the mean inter-infusion interval was 26.1 days (range: 21-35). After one course of therapy, no further paracentesis was required in four patients. However, bevacizumab was not effective in one patient and hence paracentesis had to be repeated. Due to disease progression, treatment was aborted in four patients, who died of their disease within a few months of the bevacizumab treatment (median overall survival period: 3.3 months). Conclusion: The intravenous infusion of 7.5 mg/kg bevacizumab at three- to four-week intervals is a promising therapy for malignant ascites caused by recurrent ovarian cancer.

Original languageEnglish
Pages (from-to)404-407
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume39
Issue number3
DOIs
Publication statusPublished - 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this